A failed Bush-era program aimed at curbing the cost of doctor-administered drugs might actually work if the Trump administration has the political will to revive it, a number of independent drug experts agree. The Competitive Acquisition Program, which allows third parties to negotiate with manufacturers for drugs that physicians then buy, was among the ideas included in President Donald Trump’s blueprint on lowering drug prices.